Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brooks LaboratoriesBOM:533543 -0.77%61 Gross Margin % is 38.55% as of Mar. 2026, which is 70% above its 10-year median of 22.69. GuruFocus rates BOM:533543 with a GF Score™ of 61/100 and a GF Value™ of ₹118.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Brooks Laboratories ranks worse than 64.58% on this metric.
The historical rank and industry rank for Brooks Laboratories's Gross Margin % or its related term are showing as below:
BOM:533543'
s Gross Margin % Range Over the Past 10 Years
Min: 2.02 Med: 22.69 Max: 40.49
Current: 40.49
During the past 13 years, the highestGross Margin % of Brooks Laboratories was 40.49%. The lowest was 2.02%. And the median was 22.69%.
BOM:533543's Gross Margin % is ranked worse than 64.58% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:533543: 40.49
Brooks Laboratories had a gross margin of 38.55% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Brooks Laboratories was 20.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Brooks Laboratories had a gross margin of 38.55% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Brooks Laboratories Gross Margin % Related Terms
Brooks Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:533543 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Brooks Laboratories (BOM:533543) has a Gross Margin % of 38.55% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Brooks Laboratories and its competitors. This is 70% above median its historical median of 22.69. Over the past decade, Brooks Laboratories' Gross Margin % has ranged from 2.02 to 40.49. According to the industry distribution chart, Brooks Laboratories ranks #609 out of 943 companies in the Drug Manufacturers industry, placing it in the top 64.6%.
Is Brooks Laboratories' Gross Margin % too high?
Brooks Laboratories' current Gross Margin % of 38.55% is 70% above median its 10-year median of 22.69. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 40.49. The Drug Manufacturers industry median Gross Margin % is 48.54. Brooks Laboratories' value of 38.55% is 20.6% below this industry median. Based on the distribution chart, Brooks Laboratories ranks #609 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Brooks Laboratories has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #609 out of 943 companies for Gross Margin %. This places Brooks Laboratories in the lower half of its industry. The industry median Gross Margin % is 48.54. Brooks Laboratories' value of 38.55% is 20.6% below this benchmark. Historically, Brooks Laboratories' own Gross Margin % has ranged from 2.02 to 40.49 over the past decade. While the company's 10-year median is 22.69 vs. the industry median of 48.54, Brooks Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brooks Laboratories's current Gross Margin % of 38.55% is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current Gross Margin % is 38.55%, which is 70% above median its own 10-year median of 22.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹118.02, compared to a current price of ₹69.36 — trading 41.2% below its estimated fair value. The current Gross Margin % is 38.55%, which is 70% above median its 10-year median of 22.69 and 20.6% below the Drug Manufacturers industry median of 48.54. Brooks Laboratories' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Gross Margin % is 38.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹69.36 is trading 41.2% below its estimated GF Value™ of ₹118.02.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
Gross Margin %: 38.55% (70% above median its 10-year median of 22.69)
GF Value™: ₹118.02 vs. price of ₹69.36 (41.2% below fair value)
Industry Position: 20.6% below the Drug Manufacturers median (#609 of 943)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
61GF Score
Get the complete analysis for BOM:533543
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
